The DSO deal market is returning to activity in 2026, but acquirers are fundamentally changing their approach — favoring operational integration over announcement-driven growth, and conducting deeper due diligence on practice economics before closing. The shift reflects lessons learned from the 2021-2023 acquisition binge, where several platform DSOs accumulated practices faster than they could integrate them.
Dental Bite's analysis identifies key trends in the evolving deal landscape. Multiples have compressed from the 8-12x EBITDA range at the 2022 peak to 5-8x for most platform deals, with premium multiples reserved for practices demonstrating strong same-store growth, clean financials, and operational scalability. Earn-out structures are more prevalent, tying seller compensation to post-acquisition performance. Some DSOs that over-leveraged during the buying spree are now facing financial workouts — restructuring debt, divesting underperforming locations, and negotiating with lenders on covenant relief. The PE sponsors behind these platforms are shifting from growth-at-all-costs to margin optimization and free cash flow generation.
For practice owners considering a sale, the message is nuanced. The market is active, but the terms have shifted in buyers' favor. Practices with strong EBITDA margins (above 25%), diversified payer mixes, and documented operational systems command premium multiples. Practices with owner-dependent production, thin margins, or heavy Medicaid exposure face discounted offers or outright pass. The strategic play for sellers in this market: invest 12-18 months in optimizing operations and documenting systems before going to market. The practices that sell well in 2026 are the ones that prepared in 2024.
What to watch: PE-backed DSO debt maturities in 2026-2027 — refinancing at higher interest rates will force some platforms to sell or restructure, creating buying opportunities for well-capitalized acquirers.